A
ApnimedClinical-stage biotech developing Oxnimbi (AD109), the first investigational oral pill for obstructive sleep apnea.
3 Pulse stories
O
OneMedNetOneMedNet provides a platform for curating and exchanging real-world medical imaging and clinical data from healthcare provider networks to power life sciences, AI development, and academic research.
2 Pulse stories
Total RaisedNot disclosed
Last ValuationNot disclosed
Biotech
Sector
Biotech
2017
Founded
2006
Cambridge, Massachusetts
HQ
Eden Prairie, Minnesota
Public (APMD)
Status
Public (ONMD)
Apnimed investors
ShionogiColumbia Seligman Technology and Information FundAlpha Wave GlobalMorningside VenturesColumbia ManagementNexPoint Asset ManagementSectoral Asset Management
OneMedNet investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Apnimed and OneMedNet.